DaxibotulinumtoxinA Topical Gel: Phase III data

The double-blind, U.S. Phase III REALISE 1 trial in 450 patients with moderate to severe lateral canthal lines

Read the full 186 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE